Table 1.

Safety Considerations

	Infliximab	Adalimumab	Vedolizumab	Ustekinumab	Tofacitinib
Granulomatous infection	+	+	−	−	−
Serious infection	+	+	−	−	+
Herpes zoster	−	−	−	−	+
Non-Hodgkin lymphoma	+	+	−	−	?
Demyelination	+	+	−	−	−
DVT/PE	−	−	−	−	+
Hyperlipidemia	−	−	−	−	+

DVT, deep vein thrombosis; PE, pulmonary embolism. Adapted from Sandborn WJ. Positioning biologics and small molecules in the management of moderate to severe IBD. Presented at: 2020 Virtual Advances in Inflammatory Bowel Diseases Conference; December 9-12, 2020.¹